journal
MENU ▼
Read by QxMD icon Read
search

Veterinary and Comparative Oncology

journal
https://www.readbyqxmd.com/read/29446222/engineering-controls-in-veterinary-oncology-a-survey-of-148-acvim-board-certified-oncologists-and-environmental-surveillance-in-20-specialty-hospitals
#1
K Alexander, N Northrup, D Clarke, H Lindell, T Laver
Engineering controls (EC, facility and equipment barriers between hazards and people) are used to avoid exposure to chemotherapy drugs. In this study, American College of Veterinary Internal Medicine board-certified veterinary oncologists were surveyed about their use of containment primary EC (C-PEC) and supplemental EC (closed system transfer devices, CSTD). The survey was completed by 148 (38%) of practicing diplomates. All used EC. Both C-PEC and CSTD were used at 92% of hospitals; however, US Pharmacopoeial Convention Chapter <800> (USP <800>) standards were met at only 19% of hospitals and oncologists did not know the type of C-PEC at 18% of hospitals...
February 15, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29380942/evaluation-of-a-multi-agent-chemotherapy-protocol-combining-lomustine-procarbazine-and-prednisolone-lpp-for-the-treatment-of-relapsed-canine-non-hodgkin-high-grade-lymphomas
#2
J-B Tanis, S L Mason, T W Maddox, L Blackwood, D R Killick, I Amores-Fuster, A Harper, R Finotello
The standard of care treatment for canine lymphoma is multi-agent chemotherapy containing prednisolone, cyclophosphamide, vincristine and an anthracycline such as doxorubicin (CHOP) or epirubicin (CEOP). Lomustine, vincristine, procarbazine, and prednisone (LOPP) has been evaluated as a rescue, with encouraging results; however, resistance to vincristine is likely in patients relapsing on CHOP/CEOP, and this agent may enhance LOPP toxicity without improving efficacy. The aim of this study was to evaluate responses to a modified-LOPP protocol that does not include vincristine (LPP) and is administered on a 21-day cycle...
January 30, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29380929/checkpoint-molecule-expression-by-b-and-t-cell-lymphomas-in-dogs
#3
G Hartley, R Elmslie, S Dow, A Guth
Immunotherapies targeting checkpoint molecule programmed cell death 1 (PD-1) protein were shown to be effective for treatment of non-Hodgkin lymphoma in people, but little is known about the expression of PD-1 or its ligand PD-L1 by canine lymphoma. Therefore, flow cytometry was used to analyse expression of PD-1 and PD-L1 in canine lymphoma, using fine-needle aspirates of lymph nodes from 34 dogs with B cell lymphoma (BCL), 6 dogs with T cell lymphoma (TCL) and 11 dogs that had relapsed. Furthermore, fine-needle aspirates were obtained from 17 healthy dogs for comparison...
January 30, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29363264/canine-spinal-meningiomas-and-nerve-sheath-tumours-in-34-dogs-2008-2016-distribution-and-long-term-outcome-based-upon-histopathology-and-treatment-modality
#4
K Lacassagne, K Hearon, J Berg, B Séguin, L Hoyt, B Byer, L E Selmic
The purpose of this retrospective, multicentre case series was to describe the outcome following surgery and/or radiation of spinal meningiomas and nerve sheath tumours (NSTs) based upon treatment modality, with a specific aim to evaluate the survival times and time to recurrence following treatment for each histopathological diagnosis. Our hypothesis was that the addition of radiation therapy modalities to treatment will yield longer time to recurrence of clinical signs and survival time. Thirty-four dogs met the inclusion criteria of histopathologically diagnosed extramedullary spinal meningioma or NST...
January 23, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29333737/recent-advances-in-veterinary-radiation-oncology
#5
EDITORIAL
M S Kent, M M Turek, J Farrelly
No abstract text is available yet for this article.
January 14, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29322606/association-of-tumour-infiltrating-regulatory-t-cells-with-adverse-outcomes-in-dogs-with-malignant-tumours
#6
K Sakai, S Maeda, Y Yamada, J K Chambers, K Uchida, H Nakayama, T Yonezawa, N Matsuki
Regulatory T cells (Tregs) infiltrate into a variety of tumour tissues and associate with poor prognosis in humans. However, data on association of Treg infiltration with prognosis is limited in canine tumours. The purpose of this study was to examine the number of tumour-infiltrating Tregs and its association with overall survival (OS) in dogs with malignant tumours. The following 168 canine tumours were included: 37 oral malignant melanomas (OMMs); 14 oral squamous cell carcinomas (OSCCs); 16 pulmonary adenocarcinomas (PAs); 37 mammary carcinomas (MCs); 36 mast cell tumours (MCTs) and 28 hepatocellular carcinomas (HCCs)...
January 11, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29322604/clinical-characteristics-and-outcome-in-dogs-with-small-cell-t-cell-intestinal-lymphoma
#7
K M Couto, P F Moore, A L Zwingenberger, J L Willcox, K A Skorupski
Small cell intestinal lymphoma has not been well characterized in dogs. The objective of this study was to describe clinical characteristics and outcome in dogs with small cell intestinal lymphoma. We hypothesized that affected dogs would have prolonged survival compared with high-grade gastrointestinal (GI) lymphoma. Pathology records were searched for dogs with histologically confirmed small cell GI lymphoma. Seventeen dogs with confirmed small cell intestinal lymphoma were identified, and clinical and outcome data were retrospectively collected...
January 11, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29316134/dosimetric-benefit-of-adaptive-radiotherapy-in-the-neoadjuvant-management-of-canine-and-feline-thymoma-an-exploratory-case-series
#8
C Rohrer Bley, V Meier, U Schneider
While surgery is the treatment of choice for thymomas, complete excision is not possible in a significant proportion of cases. For these patients, radiotherapy can be used as neoadjunctive, post-operative adjunctive or sole therapy. During radiotherapy, rapid biological clearance of tumour cells is often observed, requiring adaptation of the treatment plan. Adaptive radiation therapy (RT) is a dynamic process, whereby the treatment plan is altered throughout the treatment course due to changes in morphologic, functional or positioning changes...
January 8, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29314561/biodistribution-and-tolerance-of-intravenous-iodine-131-labelled-hypericin-in-healthy-dogs
#9
E Abma, K Peremans, F De Vos, T Bosmans, A M Kitshoff, S Daminet, Y Ni, R Dockx, H de Rooster
Hypericin (Hyp) is a necrosis-avid compound that can be efficiently labelled with radioiodine for both diagnostic and therapeutic purposes. Before 131 I-Hyp can be considered as a clinically useful drug in a combination therapy for canine cancer patients, evaluation of its toxicity is necessary. The aim of this study was to investigate the biodistribution and tolerance of a single dose administration of 131 I-Hyp. Three healthy dogs were included. 131 I-Hyp at a dose of 0.2 mg/kg and an activity of 185 MBq was intravenously injected...
January 4, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29314493/in-vitro-efficacy-of-a-first-generation-valosin-containing-protein-inhibitor-cb-5083-against-canine-lymphoma
#10
A Gareau, C Rico, D Boerboom, M-E Nadeau
Valosin-containing protein (VCP), through its critical role in the maintenance of protein homeostasis, is a promising target for the treatment of several malignancies, including canine lymphoma. CB-5083, a first-in-class VCP inhibitor, exerts cytotoxicity through the induction of irreversible proteotoxic stress and possesses a broad spectrum of anticancer activity. Here, we determined the cytotoxicity CB-5083 in canine lymphoma cells and its mechanism of action in vitro. Canine lymphoma cell lines were treated with varying concentrations of CB-5083 and assessed for viability by trypan blue exclusion and apoptosis by caspase activity assays...
January 4, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29314614/aberrant-expression-of-micrornas-and-the-mir-1-met-pathway-in-canine-hepatocellular-carcinoma
#11
Y-C Lai, N Ushio, M M Rahman, Y Katanoda, K Ogihara, Y Naya, A Moriyama, T Iwanaga, Y Saitoh, T Sogawa, T Sunaga, Y Momoi, H Izumi, N Miyoshi, Y Endo, M Fujiki, H Kawaguchi, N Miura
Canine hepatocellular carcinoma (HCC) is the most common primary hepatic tumour in dogs. MicroRNA (miRNA) dysregulation has been reported in human HCC and shown to have diagnostic and prognostic value; however, there are no data on miRNA expression in canine HCC. The aim of the present study was to investigate differentially expressed miRNAs in canine HCC. Analysis of miRNA expression in canine HCC tissues and cell lines by quantitative reverse transcription PCR showed that miR-1, miR-122, let-7a, and let-7g were downregulated, whereas miR-10b and miR-21 were upregulated in canine HCC...
January 3, 2018: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29271043/prognostic-significance-of-clinical-presentation-induction-and-rescue-treatment-in-42-cases-of-canine-centroblastic-diffuse-large-b-cell-multicentric-lymphoma-in-the-united-kingdom
#12
O Davies, B Szladovits, G Polton, O A Garden, C Leo, A Lara-Garcia
Canine lymphoma is a heterogeneous group of diseases and many previous studies have evaluated the response of a mixed population of lymphoma cases to one specific treatment protocol. The aim of this retrospective study was to describe the outcome and prognostic factors in 42 cases of multicentric centroblastic diffuse large B-cell lymphoma treated with either a COP-type (35%) or CHOP-type (64%) induction chemotherapy. The objective response rate to induction therapy was 94%; entire dogs had a greater rate of complete vs partial remissions than neutered dogs (P = ...
December 22, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29266697/expression-of-the-glutamine-metabolism-related-proteins-glutaminase-1-and-glutamate-dehydrogenase-in-canine-mammary-tumours
#13
J-E Ryu, H-K Park, H-J Choi, H-B Lee, H-J Lee, H Lee, E-S Yu, W-C Son
Glutamine metabolism is an important metabolic pathway for cancer cell survival, and there is a critical connection between tumour growth and glutamine metabolism. Because of their similarities, canine mammary carcinomas are useful for studying human breast cancer. Accordingly, we investigated the correlations between the expression of glutamine metabolism-related proteins and the pathological features of canine mammary tumours. We performed immunohistochemical and western blot analysis of 39 mammary tumour tissues...
December 20, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29239119/a-retrospective-review-of-acute-myeloid-leukaemia-in-35-dogs-diagnosed-by-a-combination-of-morphologic-findings-flow-cytometric-immunophenotyping-and-cytochemical-staining-results-2007-2015
#14
L L Davis, K R Hume, T Stokol
Acute myeloid leukaemia (AML) is an uncommon, rapidly progressive neoplasm in dogs. The aim of this retrospective study was to characterize the clinical presentation, haematologic findings, diagnostic imaging results, treatment and survival time of a contemporary cohort of dogs with AML. Diagnosis was based on >20% blasts in bone marrow or blood identified as myeloid based on morphologic findings, flow cytometric immunophenotyping and cytochemical staining. Medical records of 35 dogs diagnosed with AML from 2007 to 2015 were included...
December 14, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29239110/association-of-prognostic-features-and-treatment-on-survival-time-of-dogs-with-systemic-mastocytosis-a-retrospective-analysis-of-40-dogs
#15
S J Moirano, S F Lima, K R Hume, E M Brodsky
Systemic mastocytosis is a rare phenomenon, with limited information regarding prognostic features and effective treatment of canine patients with this disease. The objective of this study is to determine the impact of certain features and treatments on dogs with systemic mastocytosis. The medical records of 40 dogs from 4 northeastern US veterinary hospitals, with evidence of systemic mast cell disease, were evaluated retrospectively. Variables analysed with relation to overall survival and prognostic significance included treatment protocol used, substage, presence of a cutaneous or visceral tumour, presence of multiple cutaneous Mast cell tumours, grade of the primary tumour and metastatic site(s)...
December 14, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29235249/anticancer-effects-of-resveratrol-in-canine-hemangiosarcoma-cell-lines
#16
A Carlson, K S Alderete, M K O Grant, D M Seelig, L C Sharkey, B N M Zordoky
Hemangiosarcoma (HSA) is a highly malignant tumour with aggressive biological behaviour. HSAs are more common in dogs than other domestic animals. The median survival time of dogs with HSA remains short, even with chemotherapy and surgery. Therefore, there is a critical need to improve the adjuvant chemotherapeutic regimens to improve clinical outcomes in dogs with HSA. Resveratrol has been shown to possess strong anti-proliferative and/or pro-apoptotic properties in human cancer cell lines. Nevertheless, the potential anticancer effects of resveratrol have not been reported in canine HSAs...
December 13, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29205839/canine-nodal-marginal-zone-lymphoma-descriptive-insight-into-the-biological-behaviour
#17
M Cozzi, L Marconato, V Martini, L Aresu, F Riondato, F Rossi, D Stefanello, S Comazzi
Canine nodal marginal zone lymphoma (nMZL) is classified as an indolent lymphoma. Such lymphomas are typified by low mitotic rate and slow clinical progression. While the clinical behaviour of canine splenic MZL has been described, characterized by an indolent course and a good prognosis following splenectomy, there are no studies specifically describing nMZL. The aim of this study was to describe the clinical features of and outcome for canine nMZL. Dogs with histologically confirmed nMZL undergoing a complete staging work-up (including blood analysis, flow cytometry [FC] on lymph node [LN], peripheral blood and bone marrow, imaging, histology and immunohistochemistry on a surgically removed peripheral LN) were retrospectively enrolled...
December 4, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29205754/preliminary-investigation-of-blood-concentrations-of-insulin-like-growth-factor-insulin-lactate-and-%C3%AE-hydroxybutyrate-in-dogs-with-lymphoma-as-compared-with-matched-controls
#18
B McQuown, K E Burgess, C R Heinze
It is well established that tumour cells have metabolic differences when compared with normal cells. This is particularly true for energy metabolism in which dogs with cancer have been reported to have higher blood insulin and lactate concentrations than control dogs. Moreover, some human and animal studies suggest that the insulin-like growth factor 1 (IGF-1) signalling pathway may play a role in tumorigenesis and tumour progression. At present, IGF-1 has not been evaluated in dogs with multicentric lymphoma...
December 4, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29181871/outcome-of-9-dogs-treated-with-stereotactic-radiation-therapy-for-primary-or-metastatic-vertebral-osteosarcoma
#19
K E Swift, S M LaRue
Primary and metastatic vertebral osteosarcoma (OSA) in the dog carries an overall guarded prognosis. Previously reported definitive treatments in dogs with vertebral OSA have included surgery, radiotherapy, chemotherapy or a combination of those therapies. This retrospective study was completed to determine patterns of failure, duration of local control and survival time in dogs with vertebral OSA treated with stereotactic radiation therapy (SRT). Nine dogs were treated with SRT for vertebral OSA. Protocols ranged from 1 to 5 fractions with total prescription ranging from 13...
November 27, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/29178579/vitamin-d-receptor-expression-in-canine-mammary-gland-and-relationship-with-clinicopathological-parameters-and-progesterone-oestrogen-receptors
#20
R Sánchez-Céspedes, M D Fernández-Martínez, A Raya, C Pineda, I López, Y Millán
The vitamin D receptor (VDR) belongs to the nuclear class II receptor family. VDR is a ligand transcription factor and mediates the actions of calcitriol, the active product of vitamin D synthesis. Nowadays, it is known that the biological actions of calcitriol include the capacity to modulate cancer features, such as proliferation and differentiation, apoptosis, angiogenesis, invasion and metastasis. VDR expression has been demonstrated in human breast cancer and vitamin D has emerged as a promising targeted therapy...
November 27, 2017: Veterinary and Comparative Oncology
journal
journal
40498
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"